Zobrazeno 1 - 10
of 80
pro vyhledávání: '"F. Marc LaForce"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 5, Pp 1098-1102 (2018)
The introduction of a new Group A meningococcal conjugate vaccine, MenAfriVacR, has been a important public health success. Group A meningococcal meningitis has disappeared in all countries where the new Men A conjugate vaccine has been used at publi
Externí odkaz:
https://doaj.org/article/4f026b77fbe84b6ea01ef083a8e5f255
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 5, Pp 1103-1106 (2018)
Until recently, periodic Group A meningococcal meningitis outbreaks were a major public health problem in the sub-Saharan Africa. In 2001, the Meningitis Vaccine Project (MVP), a partnership between the World Health Organization (WHO) and PATH, a Sea
Externí odkaz:
https://doaj.org/article/0f6a6f018202449f82dfc05effb2b3fe
Autor:
Fadima C. Haidara, Ama Umesi, Samba O. Sow, Magnus Ochoge, Fatoumata Diallo, Abdulazeez Imam, Youssouf Traore, Lucy Affleck, Moussa F. Doumbia, Bubacarr Daffeh, Mamoudou Kodio, Oghenebrume Wariri, Awa Traoré, Edrissa Jallow, Beate Kampmann, Dhananjay Kapse, Prasad S. Kulkarni, Asha Mallya, Sunil Goel, Pankaj Sharma, Annamraju D. Sarma, Nikhil Avalaskar, F. Marc LaForce, Mark R. Alderson, Abdi Naficy, Steve Lamola, Yuxiao Tang, Lionel Martellet, Nancy Hosken, Evangelos Simeonidis, Jo Anne Welsch, Milagritos D. Tapia, Ed Clarke
Publikováno v:
New England Journal of Medicine. 388:1942-1955
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c448d2a062e124d9a5c10b412af59948
https://doi.org/10.1056/nejmoa2214924
https://doi.org/10.1056/nejmoa2214924
Autor:
Reza Yaesoubi, Caroline Trotter, Caroline Colijn, Maziar Yaesoubi, Anaïs Colombini, Stephen Resch, Paul A Kristiansen, F Marc LaForce, Ted Cohen
Publikováno v:
PLoS Medicine, Vol 15, Iss 1, p e1002495 (2018)
BACKGROUND:The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt. In this context, important questions remain about the performance of different vaccine policies
Externí odkaz:
https://doaj.org/article/ecd20a2f9e9e4856a881ea71608e5976
Autor:
Awa Traore, Sambhaji Shankar Pisal, Ray Borrow, Amol Chaudhari, Yuxiao Tang, Prasad S. Kulkarni, Milagritos D. Tapia, Fadima Cheick Haidara, Samba O. Sow, F. Marc LaForce, Dhananjay Kapse, Kelly Townsend-Payne, Rajeev M. Dhere, Lionel Martellet, Nancy Hosken, Mark R. Alderson, Fatoumata Diallo, Igor Smolenov, Abdi Naficy
Publikováno v:
The New England journal of medicine. 384(22)
We conducted a phase 2, observer-blinded, randomized, controlled trial involving Malian children 12 to 16 months of age. Participants were assigned in a 2:2:1 ratio to receive nonadjuvanted NmCV-5, alum-adjuvanted NmCV-5, or the quadrivalent vaccine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e11340b3e5acda5e31f3af5e38e7fb1
https://pubmed.ncbi.nlm.nih.gov/34077644
https://pubmed.ncbi.nlm.nih.gov/34077644
Publikováno v:
Viral Immunology. 31:109-113
From 2001 to 2017 the Meningitis Vaccine Project (MVP), a Gates Foundation funded partnership between PATH and the World Health Organization (WHO), successfully developed, tested, licensed, and introduced an affordable new Group A meningococcal conju
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbcf7826eec7f88734504c756a48b3af
https://doi.org/10.1089/vim.2017.0120
https://doi.org/10.1089/vim.2017.0120
Publikováno v:
Human Vaccines & Immunotherapeutics. 14:1103-1106
Until recently, periodic Group A meningococcal meningitis outbreaks were a major public health problem in the sub-Saharan Africa. In 2001, the Meningitis Vaccine Project (MVP), a partnership between the World Health Organization (WHO) and PATH, a Sea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ce03c012c9d26c74c38ba45e89c40f4
https://doi.org/10.1080/21645515.2017.1391434
https://doi.org/10.1080/21645515.2017.1391434
Autor:
Ted Cohen, Fati Sidikou, Anaïs Colombini, F. Marc LaForce, Reza Yaesoubi, S M Niaz Arifin, Christoph Zimmer, Caroline Trotter
Publikováno v:
Med Decis Making
Background. Despite the introduction of an effective serogroup A conjugate vaccine (MenAfriVac™), sporadic epidemics of other Neisseria meningitidis serogroups remain a concern in Africa. Polyvalent meningococcal conjugate (PMC) vaccines may offer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::782262ea73d3c517ded3c4025dfeabf3
https://pubmed.ncbi.nlm.nih.gov/31268405
https://pubmed.ncbi.nlm.nih.gov/31268405
Autor:
S. M. Niaz Arifin, Zimmer, Christoph, Trotter, Caroline, Colombini, Anaïs, Fati Sidikou, F. Marc LaForce, Cohen, Ted, Yaesoubi, Reza
Supplemental material, Appendix_online_supp for Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study by S. M. Niaz Arifin, Christoph Zimmer, Caroline Trotter, Anaïs Colombin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91f9c7d5915aa5c23e032bd906b66e61
Autor:
Lionel Martellet, Ray Borrow, Helen Findlow, Valerie Brown, Wilbur H. Chen, Megan L McDonough, C Rebecca Boyce, Mark R. Alderson, Prasad S. Kulkarni, Nancy Hosken, Kathleen M. Neuzil, Rajeev M. Dhere, Mardi Reymann, Marcela F. Pasetti, Len Dally, Sambhaji Shankar Pisal, F. Marc LaForce, Amol Chaudhari
Publikováno v:
The Lancet. Infectious diseases. 18(10)
Summary Background Invasive meningococcal disease is an important public health problem, especially in sub-Saharan Africa. After introduction of MenAfriVac in 2010, Neisseria meningitidis serogroup A disease has been almost eliminated from the region
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab51a9678b0748c059b6a0f3a1e8f9d6
https://pubmed.ncbi.nlm.nih.gov/30120070
https://pubmed.ncbi.nlm.nih.gov/30120070